Chia-Chi (Josh) Lin is the Director of Phase I Center, Department of Oncology, National Taiwan University Hospital and Professor, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine. He received his MD degree, PhD degree, and his specialty training in Medical Oncology at the National Taiwan University College of Medicine. He was a clinical research fellow at the Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX in 2006 and at the Clinical Research Services at Scottsdale Healthcare, Translational Genomics Research Institute, Scottsdale, AZ in 2007. He has authored more than 30 peer-reviewed manuscripts. His main research interests include early phase drug development as well as novel therapies for lung cancer, esophageal cancer, and thyroid cancer. Dr. Lin is an active member of the American Association for Cancer Research and the American Society of Clinical Oncology.

Associate Professor Thanyanan Reungwetwattana is a consultant at Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand. She received her medical degree, Thai Board of Internal Medicine, and Thai Subspecialty Board in Medical Oncology at Ramathibodi Hospital, Mahidol University, Thailand. After that, she spent 3 years from August 2009 to June 2012 as a clinical research fellow in thoracic malignancies and also obtained a Master’s Degree of Biomedical Science (Clinical Research Training Program) at the Mayo Clinic Cancer Center, Rochester, MN, USA. Subsequently, she extended her training as a Clinical Fellow in Advanced Medical Oncology focusing on Cancer Drug Development Program at Roswell Park Cancer Institute, NY, USA from July 2012 to July 2013. Dr. Reungwetwattana’s research interests are in lung cancer and drug development which involve both in clinical and translational settings. Furthermore, Dr. Reungwetwattana has served as an editorial board member and committee of the Journal of Thoracic Oncology from June 2013 to present. She is also joining the Communication Committee of the International Association for the Study of Lung Cancer (IASLC) from 2015 to present and she has been the WCLC 2017, 2019, 2021 program committee. Currently she also serves as the regional organizing committee for WCLC 2020-2021, and scientific committee for ESMO 2021. She recently received the Best Young Physician of the Year from The Royal College of Physicians of Thailand (RCPT) and she is also the National finalist of ASEAN-US Science Prize for Women 2020.

Dr. Herbert H Loong holds dual appointment as a Clinical Assistant Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase 1 Clinical Trial Centre at The Chinese University of Hong Kong. Dr Loong's clinical and research interests include experimental therapeutics, thoracic oncology, sarcoma medical oncology and neuro-oncology. He has previously served in the Communications Committee of the IASLC, and is currently completing his term as an Education Committee Member.

An oncology physician focused on the researches about Lung cancer

2001 Graduate of Nara Medical University, M.D. degree 2001-2003 Resident in Second Department of Internal Medicine, Nara Medical University Hospital 2004-2006 Research Staff, Pharmacology Division, National Cancer Center 2008- Assistant Professor, Dept Medical Oncology, Kindai University School of Medicine

Professor, Tongji University School of Medicine Cancer Institute & Director, Department of Medical Oncology, Shanghai Pulmonary Hospital

James Chih-Hsin Yang, MD, PhD, received his MD from National Taiwan University (NTU) in Taipei in 1986 and completed his PhD degree between 1996 and 2000 at the Graduate Institute of Clinical Medicine, NTU, in 2000. He first completed his internal medicine residency at the NTU Hospital, and between 1992 and 1995, he undertook medical oncology fellowship training at the National Cancer Institute at Bethesda, Maryland. He is currently the director and distinguished professor of the Graduate Institute of Oncology at National Taiwan University. He is also the director of the Department of Oncology at the National Taiwan University Hospital. He has been a staff member in the Department of Oncology at the University Hospital since 1995. Dr Yang’s research focuses on lung cancer treatment and the mechanism of resistance of chemotherapy, targeted therapy and immunotherapy. Dr Yang is a leader in lung cancer clinical studies, especially in the new drug development for lung cancer treatment. He and other Asian investigators have established EGFR TKI as the front-line treatment for lung cancer patients with EGFR mutation (IPASS). He is also the principal investigator of several studies that led to the global approval of the 2nd-generation irreversible EGFR TKI, afatinib, and the 3rd-generation EGFR TKI, osimertinib. He has published more than 250 papers in peer-reviewed scientific journals such as New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology, and has served on the editorial board of Annals of Oncology and Lung Cancer. He is the current associate editor of Journal of Thoracic Oncology and Nature Scientific Report. He received the 2nd Kobayashi Foundation Cancer Research Award from the Asian Clinical Oncology Society in 2012, the distinguished research award of the Taiwan National Science Council 2012-2015, the TECO award for biotechnology in 2015, distinguished research award of the Ministry of Science and Technology, Taiwan, from 2016-2018 and Academic Award from Taiwan Ministry of Education in 2018. Distinguished chair scholar from the Foundation on 2019-2021. National Chair Scholar from Ministry of Education from 2021-2024. He currently serves on the board of directors of the International Association for the Study of Lung Cancer (IASLC), with an appointment from 2017-2021.

Dr. Tanizaki is a medical oncologist who specializes lung cancer and molecular targeted therapy in Japan. She received MD in 2007 and PhD in 2011 at Kindai University, faculty of medicine, Japan. After having trained as postdoctoral fellow at Dana-Farber Cancer Institute, Dr, Pasi Janne’s lab, from 2012 to 2015, she is back in Japan and is one of the young leaders in Japanese medical oncology society. Her research interests are tyrosine kinase inhibitors and their resistant mechanisms in solid tumors, especially thoracic cancers.

Dr. Se-Hoon Lee is a professor in the Division of Hematology/Oncology at Sungkyunkwan University and is the faculty of Samsung Medical Center. He is a graduate of Seoul National University College of Medicine and completed post-graduate training at Seoul National University College of Medicine. He worked as a visiting scholar at Dana-Farber Cancer Institute and Broad Institute in Boston, which was supervised by Dr. Matthew Meyerson, one of the leader of The Cancer Genome Atlas. Dr. Lee’s area of research and clinical activity have focused on lung cancer. He has authored and co-authored over 300 medical articles on clinical and translational oncology and is involved in dozens of clinical trials related to lung cancer therapy and diagnostics. His research focuses on finding the association of molecular character and clinical outcomes, and new therapeutic strategy through it. In the era of immunotherapy, his research has moved to exploring genomic and transcriptomic features to predict the clinical response to immunotherapy and discover new therapeutic target for it. His recent publications include the association between genomic feature, DNA global methylation and microbiome and response to immune checkpoint inhibitors in lung cancer. Dr. Lee serves as a member of the International Association for the Study of Lung Cancer (IASLC), American Society of Clinical Oncology (ASCO) and American Association of Cancer Research (AACR).

Professional experience: 2000-2003 Rotating internship in the Niigata University Medical and Dental Hospital, Niigata City, Japan 2004-2008 Clinical fellow in Internal Medicine (II), Niigata University Medical and Dental Hospital, Niigata City, Japan 2009-2010 Research resident of Medical Oncology in the Division of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan 2011-2012 Clinical fellow in Internal Medicine (II), Niigata University Medical and Dental Hospital, Niigata City, Japan 2013-2014 Assistant Professor in Advanced Disaster Medical and Emergency Critical Center, Niigata University Medical and Dental Hospital, Niigata City, Japan 2015 Medical Doctor in Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata City, Japan 2016-Present Chief physician in Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata City, Japan